#Singapore #QDX #Giuseppe Barca #Gordon Bell

Giuseppe Barca of QDX Honored with the 2024 ACM Gordon Bell Prize

In a landmark achievement for the field of computational chemistry, Associate Professor Giuseppe Barca, co-founder of QDX, has received the esteemed 2024 ACM Gordon Bell Prize. This award, often dubbed the 'Nobel Prize of high-performance computing,' recognizes significant breakthroughs in the application of computing to challenging scientific problems. Barca leads a team dedicated to pushing the boundaries of drug discovery technology through advanced simulations and quantum chemistry.

The prize was awarded for the project titled "Breaking the Million-Electron and 1 EFLOP/s Barriers Biomolecular-Scale Ab Initio Molecular Dynamics Using MP2 Potentials," showcasing a collaborative effort involving key players from the University of Melbourne, Australian National University, QDX, Advanced Micro Devices, and Oak Ridge National Laboratory. Utilizing the state-of-the-art Frontier supercomputer, the team achieved unprecedented simulations of biological systems, marking a substantial leap forward in computational chemistry.

A/Prof Barca expressed his gratitude upon receiving the accolade, stating, "Receiving the Gordon Bell Prize is a tremendous honour. This achievement underscores the potential of high-performance computing in transforming drug discovery processes. At QDX, we are committed to leveraging these advancements to accelerate the development of novel therapeutics, ultimately improving patient outcomes." This sentiment reflects the dedication of the QDX team in enhancing their computational methodologies and outcomes.

The work spearheaded by Barca and his collaborators enhances QDX's drug discovery capabilities significantly. The newly developed simulation techniques provide remarkably accurate predictions of molecular behavior, which are essential for designing innovative therapeutics effectively and efficiently. QDX's integration of these advanced simulation methodologies has already begun to pave the way for collaboration with various pharmaceutical companies and tech startups in Australia, Singapore, and the United States, ensuring substantial impacts in the health sector.

CEO Loong Wang highlighted Barca's recognition as a testament to QDX's innovative culture, stating, "Giuseppe's recognition with the Gordon Bell Prize is a testament to the innovative spirit at QDX. His work exemplifies our mission to integrate cutting-edge computational techniques into drug discovery, paving the way for more effective treatments. We are excited to see how these advancements will continue to drive our efforts in developing solutions for complex diseases." This underscores the collective ambition to transform the nature of drug discovery.

QDX has already begun implementing these groundbreaking simulation methodologies into its operational framework. The company aims to advance these techniques further to develop the world's first in-silico simulation technology that utilizes exascale computing for precise therapeutic design. This initiative is aimed at streamlining the drug discovery pipeline, ultimately enhancing the ability to combat complex diseases more effectively.

This innovative spirit and pursuit of excellence not only highlight QDX's commitment to improving drug development but also align with the broader goals of the ACM and the scientific community at large, which seeks to encourage advancements in computational techniques. Barca's project signifies an extraordinary step forward in high-performance computing's role in science, with impactful implications for future research and healthcare solutions.

For further insights into QDX's innovative approach to drug discovery and their latest advancements, please visit www.qdx.co.

About QDX

QDX is a pioneering drug discovery firm specializing in high-performance quantum simulations designed to expedite the creation of new therapeutics. Founded by experts across life sciences, computational chemistry, and high-performance computing, QDX collaborates with global partners to formulate inventive solutions to complex diseases.

About the ACM and the Gordon Bell Prize

The Association for Computing Machinery (ACM) stands as the premier computing organization globally, devoted to fostering knowledge and innovation within the field. The Gordon Bell Prize is awarded annually to underscore exceptional achievements in high-performance computing, immortalizing the legacy of Gordon Bell, an influential figure in the realms of computer architecture and parallel computing.